The document is a regulatory filing informing about the availability of the recorded conference call for investors and analysts.
The conference call was specifically held to discuss the Financial Results of the Company for the Quarter ended June 30, 2026 (Q1 FY2027).
The audio recording of the call has been uploaded on the Company's website and is accessible via the provided link: https://www.aartidrugs.com/reports-fillings-concall-recording.
A transcript of the conference call will be shared with the Stock Exchanges (BSE Limited and National Stock Exchange of India Limited) and will also be uploaded on the Company's website (https://www.aartidrugs.com) in due course.
This is a follow-up to a previous intimation letter with reference number ADL/SE/2026-27/26 dated July 29, 2026.
Additional Notes Section
The disclosure is made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
The document itself is a compliance letter addressed to the Listing/Compliance Departments of BSE Limited and the National Stock Exchange of India Limited.
No financial data, management participant names, or strategic updates are disclosed in this specific announcement; it solely concerns the availability of the call recording and upcoming transcript.
The letter was digitally signed by Rushikesh Vivek Deole, Company Secretary & Compliance Officer (ICSI M.No.: F12932), on August 3, 2026.
